The board of directors of Luye Pharma Group Ltd. announces that all subjects under the phase I clinical trial in the People's Republic of China (``China'') for LY-CovMab, an innovative antibody product of Shandong Boan Biotechnology Co. Ltd., have completed enrollment with LY-CovMab. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19). LY-CovMab is a fully human monoclonal neutralizing antibody, which specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain with high affinity, and can effectively block the binding of the virus to the ACE2 host cell surface receptor. The results of preclinical pharmacodynamics study showed that LY-CovMab has good effects for both therapeutic and prophylactic venues against SARS-CoV-2 infection. LY-CovMab shows efficient neutralizing ability and could effectively cope with viral mutations. In addition, LY-CovMab could effectively avoid the ADE (antibody-dependent enhancement) effect. In addition to innovative antibody products, Shandong Boan also has 8 biosimilar products. For biosimilar products, Biologic License Application (BLA) has been made for LY01008 (biosimilar to Avastin) in China; LY06006 (biosimilar to Prolia) is under phase III clinical trial in China and phase I clinical trial in Europe as well as the United States; LY01011 (biosimilar to Xgeva) is under phase III clinical trial in China; LY09004 (biosimilar to Eylea) is under phase III in China.